Når darbepoetin alfa administreres subkutant, har det en længere terminal halveringstid, end når det administreres intravenøst, hvilket skyldes den subkutane absorptionskinetik.
The longer terminal half-life of darbepoetin alfa administered subcutaneously compared to intravenously is due to subcutaneous absorption kinetics.